Q2 FY2026 · ended Jun 30, 2026 · Revenue $3.69M, +27.8% YoY · Filed Aug 17, 2026
Nexgel, Inc. (NXGL) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $3.7 million and a net loss of $3.6 million. As of Jun 30, 2026 it held $492,000 in cash and investments and $3.9 million in total debt.
Revenue
$3.69M
+27.8% vs year-ago quarter
Net income
$-3.63M
-446.6% vs year-ago quarter
Operating cash flow
$-2.20M
-439.8% vs year-ago quarter
Free cash flow
$-513,000
+35.3% vs prior quarter
EPS
$-0.40
-344.4% vs year-ago quarter
Dividend per share
None
Shares outstanding
9.75M
+20.8% vs year-ago quarter
Net cash
$-3.38M
Q2 FY2026
Operating margin
-44.8%
TTM
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- NXGL (Nasdaq), NXGLW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Langhorne, PA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1468929
- Former names
- NEXGEL, INC. (until Oct 7, 2026); AquaMed Technologies, Inc. (until Nov 14, 2019)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $3.7M | $2.6M | $2.8M | $2.9M | $2.9M |
| Operating income | -$2.5M | -$958,000 | -$1.2M | -$725,000 | -$636,000 |
| Net income | -$3.6M | -$927,000 | -$970,000 | -$653,000 | -$665,000 |
| Diluted EPS | -$0.40 | -$0.11 | -$0.12 | -$0.08 | -$0.09 |
| Operating cash flow | -$2.2M | -$504,000 | $281,000 | -$785,000 | -$407,000 |
| Free cash flow | — | -$513,000 | — | -$793,000 | -$539,000 |
| Total assets | $26.4M | $11.6M | $10.5M | $11.6M | $9.7M |
| Total liabilities | $21.0M | $7.1M | $5.6M | $6.0M | $4.7M |
| Stockholders' equity | $4.9M | $4.0M | $4.5M | $5.2M | $4.7M |
| Cash and investments | $492,000 | $208,000 | $317,000 | $938,000 | $725,000 |
| Total debt | $3.9M | $3.0M | $3.1M | $3.2M | $2.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
Oct 7, 2026 | Oct 7, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 24, 2026 | Sep 24, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Sep 23, 2026 | Sep 23, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 21, 2026 | Aug 21, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 17, 2026 | Aug 17, 2026 |
| 10-Q | Quarterly report | Aug 17, 2026 | Jun 30, 2026 |
All 327 Nexgel, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.